Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada

EGFR tyrosine kinase inhibitors (EGFR-TKIs) are breakthrough palliative treatments for advanced lung cancer patients with tumors harboring mutations in the EGFR gene. Using healthcare administrative data, three cohorts were created to describe the use of three EGFR-TKIs that are publicly funded in Q...

Descripción completa

Detalles Bibliográficos
Autores principales: Qureshi, Samia, Boily, Gino, Boulanger, Jim, Golo, Kossi Thomas, Guédon, Aude-Christine, Lehuédé, Camille, Roussafi, Ferdaous, Truchon, Catherine, Strumpf, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689227/
https://www.ncbi.nlm.nih.gov/pubmed/36354696
http://dx.doi.org/10.3390/curroncol29110636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689227/
https://www.ncbi.nlm.nih.gov/pubmed/36354696
http://dx.doi.org/10.3390/curroncol29110636

Ejemplares similares